Clinical Trial Update: Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of nintedanib for HER2-negative metastatic inflammatory breast cancer was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-07-17